Industry
FTC Settles with CVS Caremark Over Insulin Price Manipulation Claims
The Federal Trade Commission has settled a lawsuit against CVS Caremark over allegations the company artificially inflated insulin prices and restricted access to diabetes treatment. The settlement resolves FTC charges related to the pharmacy benefit manager's pricing practices for insulin products. The action follows broader federal scrutiny of PBM practices affecting drug pricing and access. Terms of the settlement were not disclosed in the initial report.
Why it mattersMedicaid MCOs contracting with CVS Caremark or other PBMs for pharmacy services face potential operational changes and heightened regulatory attention to insulin pricing transparency and formulary access requirements.